Send by Wall Street Journal

France's Sanofi-Aventis SA, meanwhile, is carrying out large clinical trials of an oral MS drug called teriflunomide. Novartis will sell its drug under the [...]

Send by KDRV

"Teriflunomide is one of several agents that fall into that category," Krupp said. The study will compare the pill to a placebo to see if patients with [...]

14 Apr 2010 A Phase II study analyzed the effect of teriflunomide, an investigational oral medication for relapsing-remitting multiple sclerosis (RRMS), [...]

Oral Teriflunomide significantly reduced MS relapse rates. Teriflunomide . Oral MS drug, Teriflunomide, promising in mid-stage trial. Teriflunomide [...]

Send by Victoria Chelsea

Paris, France – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel. [...]

Send by lowes1

Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients. by lowes1 on October 15, 2010. PARIS, October 15, 2010 /PRNewswire-FirstCall/ –. – Phase III TEMSO Study Meets Goals Including Delayed [...]

Send by [email protected]

Paris (ots/PRNewswire) - Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). [...]

Send by PR Newswire: Clinical Trials &

PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two [...]

Sanofi-Aventis: Teriflunomide Reduces Multiple Sclerosis Relapse Rate ============= Article Content: Sanofi-Aventis: Teriflunomide Reduces Multiple Sclerosis Relapse Rate. ——————— [...]

Send by Josi

Teriflunomide is one of five such orally administered disease-modifying agents (used against rheumatoid arthritis) currently under investigation. Now, a Phase II trial conducted by researchers at the Mount Sinai School of Medicine [...]

Send by news.yahoo.com

Swiss drugmaker Novartis AG's multiple sclerosis pill Gilenya won U.S. backing, putting it ahead of German rival Merck KGaA in the race to be first with an oral treatment in the United States. [...]

Send by tscott

Phase II studies have also evaluated teriflunomide as an add-on treatment to interferon-beta or glatiramer acetate in relapsing remitting MS patients and the effect of teriflunomide on people at high risk for MS—those who have [...]

Send by insciences

Paris, France – August 30, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in [...]

New one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS) wasannounced. Study results demonstrated an improvement in outcomes, [...]

Sanofi-aventis announced Monday results from a Phase III trial for its oral, multiple sclerosis drug, teriflunomide that showed significantly reduced relapse rates at two years for patients receiving the treatment, compared to placebo. [...]

Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate at 2 years versus placebo in patients with relapsing multiple sclerosis , thus achieving the [...]

Send by tscott

The TOPIC Study is a clinical research study testing the safety and effectiveness of Teriflunomide, an oral investigational medication for those at high risk of developing multiple sclerosis (MS). This study, which is sponsored by [...]

Sanofi-Aventis SA’s experimental oral medicine teriflunomide significantly reduced the relapse rate in multiple sclerosis patients, meeting the goal of a late- stage study. [...]

Send by www.redorbit.com

PARIS , October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study [...]

Teriflunomide is a new disease modifying drug being investigated for the treatment of multiple sclerosis with a comprehensive clinical development program which has been launched in monotherapy. First Phase II study results of the [...]

Send by GLG Expert Contributor

The results of a phase II trial in MS were presented in which baseline therapy with IFN-beta was compared to the combination with teriflunomide 7 and 14mg/d per oral treatment. The trial disclosed a. [...]

Send by Jean-Marc Burgunder

Teriflunomide is an orally anti-inflammatory substance with an action against proliferation of B and T cells through inhibition of dihydroorotate dehydrogenase.In an experimental model of mutiple sclerosis teriflunomide delayed disease [...]

Peer reviewed article authored by (Clemens Warnke, Gerd Meyer zu Hörste, Hans-Peter Hartung, Olaf Stüve, et al.). Read article or submit your manuscript for publishing. [...]

Summary: Investigators worldwide are recruiting people at high risk for multiple sclerosis (MS) for a study comparing two doses of oral HMR1726 (teriflunomide), an immune system-modulating agent, and inactive placebo. [...]

Send by enterprizefinancial

Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients Paris, June 7, 2010 (ots/PRNewswire) – Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, [...]